Since SMARCA4-DTT is often misdiagnosed as a carcinoma of unknown primary origin or as an undifferentiated carcinoma (Yoshida et al. 2017), nuclear medicine clinicians should include this disease in their list of differential diagnoses. This evidence concerns the gene SMARCA4 and carcinoma.